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For type-C and lentiviruses, including human immunodeficiency virus type 1 (HIV-1), the pathway of virus assembly remains
poorly defined, and the assembly and budding of capsids are believed to occur simultaneously at the plasma membrane of
the infected cell. We have now identified two putative HIV-1 assembly intermediate complexes in infected CD41 T cells. The
first of these intermediates, a detergent-resistant complex (DRC), was identified as a large oligomer that had a density of
1.10–1.13 g/ml and was primarily composed of Pr55Gag and Pr160Gag-Pol precursors. The other putative intermediate was a
detergent-sensitive complex (DSC) with a density of 1.15–1.17 g/ml, which apparently represented the products of extensive
proteolytic processing of both the Pr55Gag and Pr160Gag-Pol precursors. Both complexes could be distinguished from released
mature virions as well as immature viral particles. Surprisingly, the formation of DRC was not dependent upon the
myristylation at the N-terminus of the Gag proteins, a signal required for plasma membrane targeting and virus production.
However, the myristic acid modification was essential for the formation of DSC. These data suggest that interactions between
individual Gag molecules and between Gag and Gag-Pol precursors may occur before their targeting to the plasma
membrane during HIV-1 assembly. However, formation of the late virus assembly complex and productive processing of
Pr55Gag and Pr160Gag-Pol precursors apparently do not occur until these precursors are targeted to the plasma membrane.
© 1998 Academic Press
INTRODUCTION
Extensive mutagenesis and electron microscopic
analyses have been used to study the assembly of ret-
roviruses (reviewed in Gelderblom, 1991; Wills and Cra-
ven, 1991; Hunter, 1994; Coffin, 1996). Early electron mi-
croscopic studies have revealed two different patterns of
retroviral particle formation: In the case of type C retro-
viruses, including Rous sarcoma virus (RSV), murine leu-
kemia virus, and lentiviruses such as HIV-1, the assembly
of viral capsids has been observed only at the plasma
membrane, where virus budding eventually takes place.
In these viruses it is believed that all the viral compo-
nents (including Gag and Gag-Pol precursors, the viral
RNA genome, and viral Env glycoproteins) are individu-
ally targeted to the inner face of the plasma membrane,
where virus assembly is initiated. In contrast, assembly
of the type B and type D retroviruses, which include the
mouse mammary tumor virus and Mason–Pfizer monkey
virus (M-PMV), respectively, appears to involve transport
of the newly synthesized Gag and Gag-Pol precursors to
a specific intracytoplasmic site at which immature viral
capsids are formed. The preformed viral capsids are
then targeted to the plasma membrane, wrapped by
cellular lipid membrane containing viral Env glycopro-
teins, and released as budding viral particles (Rhee and
Hunter, 1990, 1991; Rhee et al., 1990).
For both type C and type B/D retroviruses, the Gag
polyprotein alone is necessary and sufficient for the
assembly and release of virus-like particles (Wills and
Craven, 1991; Hunter, 1994). Detailed mutagenic analysis
of RSV and other retroviruses has identified three func-
tional domains in Gag proteins that are important for
virus assembly (Wills and Craven, 1991). The M domain,
which is responsible for targeting and association with
the plasma membrane, is located in the matrix protein
(MA) of Gag precursors. The I domain, which is thought
to be important for intermolecular interaction between
Gag molecules, is part of the capsid and nucleocapsid
proteins. A position-independent late budding domain (L
domain) has recently been identified for RSV (Wills et al.,
1994; Parent et al., 1995; Xiang et al., 1996) and lentivi-
ruses (Gottlinger et al., 1991; Huang et al., 1995; Yu et al.,
1995) and shown to be required for efficient release of
budding particles.
The Gag polyprotein of HIV-1 is first synthesized as a
precursor of 55 kDa (Pr55Gag). It is subsequently cleaved
by a viral protease encoded by the pol gene to yield
mature proteins (from the N- to the C-terminus): p17
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(MA), p24 (CA), p2 spacer peptide, p7 (NC), p1 spacer
peptide, and p6. All of these cleaved Gag proteins have
been detected in mature virions (Henderson et al., 1988).
As is true in most retroviruses, the Pol precursor of HIV-1
is translated by a 21 frameshifting mechanism as a
Gag-Pol fusion protein (Jacks et al., 1988; Wilson et al.,
1988). The Gag-Pol precursor of 160 kDa (Pr160Gag-Pol) is
also cleaved by the viral protease to yield several key
viral enzymes: the protease itself (PRp11), reverse tran-
scriptase (RTp66/51), and integrase (INp34).
Like the Gag proteins of most retroviruses, the Pr55Gag
precursors of HIV-1 are also cotranslationally modified
by the addition of myristic acid at the N-terminal glycine
residue (Towler et al., 1988; Gheysen et al., 1989; Gott-
linger et al., 1989; Jacobs et al., 1989). It has been shown
that unmyristylated HIV-1 Gag proteins fail to associate
with the membrane (Zhou et al., 1994). As a result, as-
sembly of any visible electron-dense crescent-shaped
budding viral particles on the plasma membrane and
extracellular particle formation do not take place (Ghey-
sen et al., 1989; Gottlinger et al., 1989; Bryant and Ratner,
1990). In contrast, unmyristylated Gag proteins in type D
retroviruses are preassembled into immature capsids
within the cytoplasm, but these preformed capsids are
not targeted to the plasma membrane, and they accu-
mulate within the cytoplasm (Rhee and Hunter, 1987).
Despite the differences in their pathways for viral mor-
phogenesis, myristylation at the N-terminus of Gag pro-
teins is essential for viral particle release in both types of
retrovirus.
In the case of type C retroviruses and lentiviruses, the
steps that precede the formation of electron-dense bud-
ding structures at the plasma membrane are not well
defined. It is possible that all the viral components, such
as Gag, Gag-Pol, and the viral RNA genome, are individ-
ually targeted from the cytoplasm to the plasma mem-
brane from which the budding viral particles are re-
leased. At the time of budding, the viral Env glycoproteins
would be incorporated into the budding viral particles.
Alternatively, some of the viral proteins, including the
nascent Gag and Gag-Pol precursors, could form some
sort of electron-transparent complex in the cytoplasm
that is subsequently targeted to the site of virus budding.
On the basis of the currently available evidence, it is not
possible to distinguish between these two alternatives.
In order to investigate the pathway for HIV-1 morpho-
genesis, we have designed a series of experiments to
detect putative HIV-1 assembly intermediate complexes
in infected CD41 T cells. Two intermediate complexes
were found: a large, lower-density detergent-resistant
complex (DRC) that consisted mainly of Pr55Gag and
Pr160Gag-Pol precursor molecules and a detergent-sensi-
tive complex (DSC) that predominantly contained
cleaved viral proteins and had a density similar to that of
the released viral particles. Transformation of DRC into
DSC and formation of extracellular viral particles were
blocked in the N-myristylation2 mutant of HIV-1 Gag and
Gag-Pol proteins. These findings shed light on the early
steps in the viral assembly pathway in HIV-1 and may
clarify the interaction of Pr55Gag and Pr160Gag-Pol precur-
sors with cellular components during HIV-1 morphogen-
esis.
RESULTS
A detergent-resistant assembly intermediate complex
is present in HIV-1-infected CD41 T cells
To detect viral assembly intermediates that might be
produced during morphogenesis in HIV-1, we adapted a
protocol that has been successfully used to identify the
capsid structure of M-PMV, a type D retrovirus, in trans-
fected cells (Rhee and Hunter, 1990). The postnuclear
supernatant from HIV-1-infected CD41 T cells was
treated with a nonionic detergent, Triton X-100, and the
detergent-treated sample was separated on a discontin-
uous sucrose equilibrium-density gradient (Fig. 1). Each
fraction was collected and then centrifuged at high
speed to pellet high molecular weight complexes. The
pelleted complexes were resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE),
and the viral proteins were visualized by immunoblotting
(Fig. 2).
Viral proteins in the form of high-molecular-weight
complexes were detected in HIV-1-infected (Fig. 2B) but
FIG. 1. Schematic diagram outlining the identification and character-
ization of putative viral assembly intermediate complexes in HIV-1-
infected CD41 T cells.
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not in uninfected H9 CD41 T cells (data not shown) with
an HIV-11 human serum. Most viral proteins from in-
fected cells were sedimented in fractions 8–10 of the
sucrose equilibrium-density gradient at a density of 1.10
to 1.13 g/ml, with a peak at fraction 9 (Fig. 2A). The viral
proteins detected by the HIV-11 human serum were
Pr55Gag and Pr160Gag-Pol polyprotein precursors. No
cleaved mature viral Gag proteins, such as CAp24, was
detected by the HIV-11 human serum (Fig. 2B) or a
CAp24-specific rabbit polyclonal antiserum (data not
shown). Immunoblotting with a mouse monoclonal anti-
body recognizing RTp66 revealed that the Pr160Gag-Pol
precursors, two smaller RTp66-related viral proteins, and
mature RTp66 proteins also cosedimented with Pr55Gag
precursors at fractions 8, 9, 10, and 11 of the gradient
(Fig. 2C). This observation suggests that a DRC contain-
ing mostly Pr55Gag and Pr160Gag-Pol precursors is formed
in infected CD41 T cells.
Formation of the DRC was not cell-type dependent.
The same DRC was also detected in other HIV-1-infected
CD41 T cells such as SupT-1 and Jurkat (data not
shown). Furthermore, it was also detected in transfected
HeLa or COS cells (data not shown), in which most
previous investigations for HIV-1 assembly have been
performed. Formation of the DRC could also be detected
in acutely infected CD41 T cells (data not shown).
It is possible that the viral proteins in the DRC complex
had acquired their density as a result of an association
with polysomes. It has been demonstrated that treatment
with 10 mM EDTA can efficiently dissociate polyriboso-
mal complexes (Sakalian et al., 1996). However, the de-
tection of cell-associated DRC was not affected when the
samples were treated with 10 mM EDTA prior to the
gradient purification (data not shown). Also, pretreatment
of infected cells with 10 mM puromycin that has been
shown to disassociate ribosomes from RNA (Fontoura et
al., 1997) did not affect the detection of DRC from infected
CD41 T cells (data not shown). Therefore, the cofraction-
ation of Pr55Gag and Pr160Gag-Pol precursors and two
RTp66-related viral proteins of DRC apparently did not
reflect an association with polysomal complexes.
The detection of DRC was also not dependent on the
cell lysis procedure. In addition to homogenizing the cell,
we directly lysed HIV-1-infected CD41 T cells in PBS
solution containing 1% Triton X-100. DRC containing
Pr55Gag, Pr160Gag-Pol precursors, and two RTp66-related
viral proteins were also detected under these conditions
(data not shown).
DRC can be distinguished from both the released
mature and the immature viral particles
The properties of the intracellular DRC were distinctly
different from those of the released extracellular mature
HIV-1 virions. First, the released mature virions from the
same infected H9 CD41 T cells were sedimented in
fractions 5–7 of the gradient at a density of 1.15 to 1.17
g/ml, greater than that of the intracellular DRC (Fig. 3A,
top). This density is consistent with that reported for
mature virions of HIV-1 (Popovic et al., 1984; Jones et al.,
1990; Wang and Barklis, 1993). Second, in contrast to the
intracellular DRC, which contained mainly unprocessed
Pr55Gag, the released mature virions consisted predom-
inantly of cleaved mature Gag proteins, including CAp24
FIG. 2. Identification of a detergent-resistant complex (DRC) in HIV-
1-infected H9 CD41 T cells. (A) Homogenates from infected H9 CD41
T cells were treated with 1% Triton X-100 and subjected to a 16–60%
discontinuous sucrose equilibrium-density gradient as described un-
der Materials and Methods. Eighteen fractions were collected from the
bottom of the gradient. (B) To detect high-molecular-weight complexes
containing putative viral assembly intermediates, each fraction was
pelleted by a high-speed centrifugation and analyzed by SDS–PAGE
and immunoblotting with an HIV-11 human serum. (C) A mouse mono-
clonal anti-RTp66 antibody was used to recognize RTp66-related viral
proteins. The arrowheads indicate two RTp66-related viral proteins of
Pr160Gag-Pol precursors. Lanes V and M show the protein profile of
released mature HIV-1 viral particles (indicated at left) and molecular
mass markers in kDa (indicated at right), respectively. The density of
fractions 8–12 is 1.10–1.13 g/ml.
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and MAp17 (compare Figs. 2B and 3A). Third, exposure
to 1% Triton X-100 caused disruption of the released
mature virions (Fig. 3A, bottom), but not of the intracel-
lular DRC (Fig. 2B).
The intracellular DRC was also different from the re-
leased immature HIV-1 particles. It has been previously
reported that a mutation altering the active site aspartic
acid in the viral protease results in failure to process
Pr55Gag precursors (Park and Morrow, 1992). Immature
HIV-1 particles released from H9 CD41 T cells infected
with the aspartic acid-substituted HIV-1 protease mutant
also sedimented at a density of 1.15–1.17 g/ml (Fig. 3B,
top), again at a higher density than that of the intracel-
lular DRC. Furthermore, when immature HIV-1 particles
were treated with 1% Triton X-100 to solubilize their lipid
membrane, the particles sedimented at the bottom of the
gradient (Fig. 3B, bottom), with a density of approximately
1.23 g/ml, again greater than that of the DRC. It has been
demonstrated that naked immature HIV-1 capsid struc-
tures are more dense than immature viral particles with
lipid membrane intact (Lingappa et al., 1997).
DRC is not enveloped by cellular lipid membranes
We then examined the possibility that the DRC repre-
sented budding of viral structures into an intracellular
membrane such as that of the ER or Golgi apparatus. We
reasoned that the Gag and Gag-Pol proteins should be
accessible to trypsin or other proteases if the DRC were
not surrounded by a cellular lipid membrane. Therefore,
we incubated the postnuclear supernatant from infected
cells with trypsin prior to Triton X-100 treatment. After a
30-min incubation, the trypsin activity was specifically
inhibited by addition of excess trypsin inhibitor. The DRC
was detected in fractions 8–10 of the sucrose gradient in
the absence of trypsin treatment (Fig. 4A, top), but not
after exposure to trypsin (Fig. 4A, bottom). In contrast, the
viral Gag and Pol structural proteins of released HIV-1
viral particles, which are protected by the viral lipid
membrane, were not affected by trypsin digestion under
the same conditions (Fig. 4B). As a positive control for
trypsin activity, we successfully digested the surface
glycoprotein gp120 of released viral particles (data not
shown). Digestion with protease K yielded results anal-
ogous to those obtained with trypsin (data not shown).
The results obtained in the protease digestion exper-
iments were supported by the fact that we were unable
to detect any intracellular viral particles by transmission
electron microscopy (TEM) in the infected H9 CD41
cells. We examined 40 infected cells by TEM and saw no
recognizable electron-dense viral complexes or imma-
ture virion-like particles in either the intracellular mem-
brane compartment or the cytoplasm (data not shown).
It is possible that the Pr55Gag oligomers have, by
chance, exactly the same density as the Pr160Gag-Pol
oligomers, with the RTp66-related viral proteins cosedi-
menting at the same fraction in our discontinuous su-
crose gradient. The physical interactions among Pr55Gag
and Pr160Gag-Pol precursors and RTp66-related viral pro-
teins in the DRC were also analyzed by gel filtration
using a Sepharose CL-2B size column. The Pr55Gag pre-
cursors in the purified DRC from fraction 9 of the discon-
tinuous sucrose gradient were coeluted with the
Pr160Gag-Pol precursors and RTp66-related viral proteins
in the void volume of this column (data not shown).
These data indicated that the DRC represents a com-
plex of the Pr55Gag, Pr160Gag-Pol, and RTp66-related
viral proteins that has a molecular mass greater than
1.1 3 108 Da.
Neither the pol gene product nor the protease activity
of HIV-1 is required for the formation of the DRC
We have previously established H9 CD41 T cell lines
that constitutively express HIV-1 Pr55Gag precursors in
the absence of the pol gene products (DPOL) or express
Pr55Gag and Pr160Gag-Pol precursors in the context of an
aspartic acid-substituted protease mutation (Pr2). Both
the expression of Pr55Gag precursors and the release of
immature virion-like particles in the established DPOL
cell line were confirmed by immunoblotting with the
HIV-11 human serum (data not shown). Immunoblot
analysis using the HIV-11 human serum consistently
showed that the Pr55Gag precursors in the DPOL cells
formed a high-speed pelletable viral complex exclusively
at a density of 1.10–1.13 g/ml (Fig. 5A). Thus, pol gene
products are apparently not required for the formation of
a high-speed pelletable DRC-like complex. In this DPOL
cell line, neither the Pr160Gag-Pol precursors nor the
RTp66 mature viral proteins were detected in the pellet-
able DRC-like complex by immunoblotting with either the
HIV-11 human serum (Figs. 5A and 5C) or the mouse
monoclonal RTp66 antibody (Fig. 5D).
The Pr2 cell line contains a point mutation in the HIV-1
genome in which the viral protease active site aspartic
acid is substituted by alanine (Park and Morrow, 1992).
DRC was also detectable in this cell line by identical
procedures. Immunoblotting with the HIV-11 human se-
rum showed that the Pr55Gag and Pr160Gag-Pol precursors
in the H9 Pr2 cell line cosedimented in fractions 8–10 of
the gradient (Fig. 5B). Thus, the formation of a DRC-like
complex did not require the protease activity of HIV-1.
To address the possibility that the two RTp66-related
viral proteins present in the DRC were the products of
specific proteolytic processing by the HIV-1 viral pro-
tease rather than nonspecific cleavage by cellular pro-
teases, we made use of the DPOL, Pr2, and wild-type
virus-infected H9 CD41 T cell lines. Immunoblotting with
both the HIV-11 human serum (Fig. 5C) and the mouse
monoclonal anti-RTp66 antibody (Fig. 5D) revealed the
presence of the two RTp66-related viral proteins in frac-
tions 8–11 in wild-type virus-infected cells but not in the
82 LEE AND YU
FI
G
.4
.T
ry
ps
in
di
ge
st
io
n
an
al
ys
is
of
D
R
C
an
d
re
le
as
ed
m
at
ur
e
vi
ra
l
pa
rt
ic
le
s.
(A
)
A
s
de
sc
rib
ed
in
Fi
g.
2,
th
e
po
st
nu
cl
ea
r
su
pe
rn
at
an
t
of
H
IV
-1
-in
fe
ct
ed
H
9
C
D
41
T
ce
ll
ho
m
og
en
at
e
w
as
ob
ta
in
ed
an
d
di
vi
de
d
in
ha
lf.
O
ne
ha
lf
w
as
in
cu
ba
te
d
w
ith
5
m
g/
m
lt
ry
ps
in
at
37
°C
fo
r
30
m
in
(A
,b
ot
to
m
).
Th
e
ot
he
r
ha
lf
w
as
al
so
in
cu
ba
te
d
w
ith
ou
t
tr
yp
si
n
as
a
co
nt
ro
l(
A
,t
op
).
A
fte
r
in
cu
ba
tio
n,
ex
ce
ss
an
tit
ry
ps
in
in
hi
bi
to
r
w
as
ad
de
d
to
sp
ec
ifi
ca
lly
in
hi
bi
t
fu
rt
he
r
pr
ot
eo
ly
tic
di
ge
st
io
n.
D
R
C
w
er
e
an
al
yz
ed
by
tr
ea
tm
en
tw
ith
1%
Tr
ito
n
X-
10
0,
ce
nt
rif
ug
at
io
n,
an
d
im
m
un
ob
lo
tti
ng
w
ith
an
H
IV
-1
1
hu
m
an
se
ru
m
as
de
sc
rib
ed
in
Fi
g.
2.
Th
e
de
ns
ity
of
fr
ac
tio
ns
8–
12
is
1.1
0–
1.1
3
g/
m
l.
(B
)
Th
e
re
le
as
ed
m
at
ur
e
vi
ra
lp
ar
tic
le
s
w
er
e
ha
rv
es
te
d
fr
om
a
ce
ll
cu
ltu
re
su
pe
rn
at
an
t
of
H
IV
-1
-in
fe
ct
ed
H
9
C
D
41
T
ce
lls
,r
es
us
pe
nd
ed
in
hy
po
to
ni
c
bu
ffe
r
so
lu
tio
n,
ho
m
og
en
iz
ed
,
an
d
di
vi
de
d
in
to
tw
o
al
iq
uo
ts
.
E
ac
h
al
iq
uo
t
w
as
in
cu
ba
te
d
w
ith
or
w
ith
ou
t
5
m
g/
m
l
tr
yp
si
n
as
de
sc
rib
ed
ab
ov
e.
Fr
ac
tio
na
te
d
sa
m
pl
es
w
er
e
ag
ai
n
ch
ar
ac
te
riz
ed
by
S
D
S
–P
A
G
E
an
d
im
m
un
ob
lo
tti
ng
w
ith
an
H
IV
-1
1
hu
m
an
se
ru
m
.T
he
de
ns
ity
of
fr
ac
tio
ns
5–
7
is
1.1
5–
1.1
7
g/
m
l.
La
ne
V,
pr
ot
ei
n
pr
of
ile
of
m
at
ur
e
vi
ra
lp
ro
te
in
s
P
r5
5G
a
g
,C
A
p2
4,
M
A
p1
7,
an
d
RT
p6
6;
la
ne
M
,m
ol
ec
ul
ar
m
as
s
m
ar
ke
rs
.
83HIV-1 ASSEMBLY
FI
G
.5
.A
ss
es
sm
en
t
of
H
IV
-1
vi
ra
lp
ro
te
as
e
in
vo
lv
em
en
t
in
pr
oc
es
si
ng
of
P
r1
60
G
a
g
-P
o
l
pr
ec
ur
so
rs
in
D
R
C
.T
w
o
m
ut
an
t
H
9
C
D
41
T
ce
ll
lin
es
,D
P
O
L
an
d
P
r2
,
w
er
e
ge
ne
ra
te
d
as
de
sc
rib
ed
un
de
r
M
at
er
ia
ls
an
d
M
et
ho
ds
.B
ot
h
D
P
O
L
(A
)
an
d
P
r2
(B
)
ce
ll
ho
m
og
en
at
es
w
er
e
fr
ac
tio
na
te
d
by
su
cr
os
e
eq
ui
lib
riu
m
-d
en
si
ty
ce
nt
rif
ug
at
io
n
an
d
an
al
yz
ed
by
S
D
S
–P
A
G
E
an
d
im
m
un
ob
lo
tti
ng
w
ith
an
H
IV
-1
1
hu
m
an
se
ru
m
.(
C
)
A
fte
r
an
al
og
ou
s
su
cr
os
e
eq
ui
lib
riu
m
-d
en
si
ty
ce
nt
rif
ug
at
io
n,
fr
ac
tio
ns
8–
11
co
nt
ai
ni
ng
D
R
C
-li
ke
co
m
pl
ex
es
fr
om
D
P
O
L,
P
r2
,a
nd
H
IV
-1
-in
fe
ct
ed
H
9
C
D
41
T
ce
lls
w
er
e
an
al
yz
ed
by
im
m
un
ob
lo
tti
ng
w
ith
th
e
H
IV
-1
1
hu
m
an
se
ru
m
(C
)a
nd
a
m
ou
se
m
on
oc
lo
na
la
nt
i-R
Tp
66
an
tib
od
y
(D
).
A
rr
ow
he
ad
s
in
di
ca
te
RT
p6
6-
re
la
te
d
cl
ea
va
ge
in
te
rm
ed
ia
te
s
of
P
r1
60
G
a
g
-P
o
l
pr
ec
ur
so
rs
.L
an
e
V
an
d
la
ne
V
(W
T)
,p
ro
te
in
pr
of
ile
s
of
re
le
as
ed
m
at
ur
e
H
IV
-1
vi
ra
lp
ar
tic
le
s;
la
ne
V
(P
r2
),
pr
of
ile
of
re
le
as
ed
im
m
at
ur
e
vi
ra
lp
ar
tic
le
s;
la
ne
M
,m
ol
ec
ul
ar
m
as
s
m
ar
ke
rs
.
D
en
si
ty
of
fr
ac
tio
ns
8–
12
,1
.10
–1
.13
g/
m
l.
84 LEE AND YU
DPOL or Pr2 cells. These findings indicated that the
cosedimentation of RTp66-related viral proteins did not
result from nonspecific cleavage by host cell proteases.
A second putative assembly intermediate that is
detergent-sensitive is present in HIV-1-infected
CD41 T cells
We next examined the question of whether the DRC
might progress to form other viral assembly intermedi-
ates in infected CD41 T cells, intermediates that might
have been disrupted by the nonionic detergent used
under our original experimental conditions. This possi-
bility reflects the fact that, unlike immature viral particles,
the released mature viral particles are easily disrupted
by nonionic detergents (Park and Morrow, 1992; Wang
and Barklis, 1993). We therefore analyzed postnuclear
supernatants from infected cell homogenates as previ-
ously described (Fig. 1), but without pretreating the post-
nuclear supernatant from infected cell homogenates with
Triton X-100.
Immunoblotting with the HIV-11 human serum indi-
cated the presence of DRC in fractions 9 and 10 of the
gradient (Fig. 6A) in postnuclear supernatants that had
not been exposed to Triton X-100. However, a second
distinct viral complex, consisting predominantly of ma-
ture CAp24 and MAp17 (Fig. 6A) and RTp66 (Fig. 6B), was
detected in fractions 5–7 of the gradient. Since this viral
complex was not detected in the presence of Triton
X-100, we referred it to a detergent-sensitive complex
(DSC). Substantial quantities of RTp66 mature proteins
were cofractionated with CAp24 and MAp17 proteins in
the DSC, whereas the quantities of Pr160Gag-Pol precur-
sors and two RTp66-related cleavage intermediates were
dramatically decreased compared to DRC (Fig. 6). There-
fore, the two putative viral assembly intermediates, DRC
and DSC, could be distinguished from each other not
only by their sensitivity to nonionic detergent but also by
their relative densities and by the extent of the viral
protein processing that was evident in each complex.
The density and viral protein profile of DSC were very
similar to those of the released mature HIV-1 particles.
Therefore, we again performed a protease digestion
analysis to try to distinguish the DSC from released
mature virions. Treatment of the postnuclear supernatant
from infected cell homogenates with protease K dis-
rupted the majority of the viral complexes in the case of
both DRC and DSC (Figs. 7A and 7B). In contrast, pro-
tease K had little effect on the released mature virions
under the same conditions (Figs. 7D and 7E).
We also compared the sensitivity of the intracellular
viral complexes and of released mature virions to treat-
ment with high salt. Exposure of the postnuclear super-
natant from infected cell homogenates to 1 M NaCl
clearly altered the density and the migration pattern of
the intracellular viral complexes in the equilibrium den-
sity gradient. Most of the DSC, which is characterized by
the extensive cleavage of viral proteins, was sedimented
into fractions 2–5 (Fig. 7C) at a density of 1.18–1.22 g/ml
after high salt treatment (data not shown), compared to
fractions 5–7 in the absence of salt treatment (Fig. 7A). In
the case of the DRC, the Pr55Gag and Pr160Gag-Pol pre-
cursors were shifted from fractions 9–11 (Fig. 7A) to
fractions 15–18 (Fig. 7C), indicating a density of 1.07–1.02
g/ml (data not shown). The results of control experiments
showed that 1 M NaCl treatment had no effect on the
sedimentation behavior of the released extracellular viri-
ons (Figs. 7D and 7F).
Myristic acid modification of the Gag proteins is not
required for the formation of the DRC but is essential
for the formation of the DSC
For type C retroviruses, membrane targeting of trans-
lated Gag polyproteins to the inner face of the plasma
membrane is essential for virus assembly and budding
(for a review see Gelderblom, 1991; Wills and Craven,
1991; Hunter, 1994). In the case of HIV-1, membrane
targeting of nascent Gag precursors requires myristic
acid modification of the amino terminus of the Gag pre-
cursors, and mutations that block the myristylation of the
Pr55Gag abolish virus production (Gheysen et al., 1989;
Gottlinger et al., 1989; Jacobs et al., 1989; Bryant and
Ratner, 1990; Wang and Barklis, 1993). However, it is not
clear whether unmyristylated Pr55Gag and Pr160Gag-Pol
proteins of HIV-1 can initiate any protein–protein interac-
tion or are capable of forming an assembly intermediate
complex in the cell. To study the requirements for myri-
stylation we generated a stable CD41 T cell line (Myr2)
that constitutively expresses unmyristylated Pr55Gag and
Pr160Gag-Pol proteins as described under Materials and
Methods.
We first asked whether unmyristylated Gag and Gag-
Pol proteins were capable of forming DRC. As we had
observed in wild-type virus-infected CD41 T cells (Myr1)
(Fig. 8A), DRC containing unmyristylated Pr55Gag and
Pr160Gag-Pol precursors were present in fractions 8–11 at
the density of 1.10–1.13 g/ml in the gradient (Fig. 8B) in
homogenates from Myr2 cells. When the samples from
wild-type Myr1 and mutant Myr2 cells were adjusted to
contain comparable amounts of Pr55Gag proteins, there
seemed to be slightly more Pr160Gag-Pol precursors in the
DRC from the mutant Myr2 cells (Figs. 8A and 8B). This
observation was confirmed by the immunoblotting with
the monoclonal anti-RTp66 antibody (Fig. 8C) under con-
ditions in which the protein loading was normalized in
terms of the quantity of Pr55Gag present. In addition,
there seemed to be less of the RTp66-related cleavage
intermediates of Pr160Gag-Pol in the DRC from the Myr2
cells than from the Myr1 cells (Fig. 8C) (see Discussion).
Next we examined whether unmyristylated Gag and
Gag-Pol proteins could form DSC. The postnuclear su-
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pernatants from the mutant Myr2 cells were incubated in
the presence or absence of 1% Triton X-100 and then
subjected to sucrose equilibrium-density centrifugation.
In contrast to the results obtained for the wild-type virus-
infected cell line (Fig. 6A), only the DRC was detected in
the mutant Myr2 cells, even in the absence of Triton
X-100 treatment (Fig. 8D, top). Little difference was seen
between the DRC that were detected in the presence or
the absence of Triton X-100 (Fig. 8D). Identical observa-
tions were made in HeLa cells, indicating that this ob-
servation is not cell-type dependent (data not shown).
In addition to analyzing virus assembly of the myristic
acid2 mutant, we performed an in vitro assembly analysis
to determine whether the Pr55Gag proteins of HIV-1 might
assemble into a distinct oligomeric form of a high-speed
pelletable DRC-like complex such as that seen in the DPol
cell line. When the in vitro transcription/translation reaction
was performed without addition of exogenous lipid, a com-
plex form of Pr55Gag polyproteins (similar to DRC) was
found in fractions 9–11 at a density of 1.10–1.12 g/ml as
analyzed by discontinuous sucrose equilibrium-density gra-
dient (data not shown). This result also supports the idea
that the Pr55Gag and/or Pr160Gag-Pol precursors may assem-
ble into a distinct oligomeric form of viral assembly inter-
mediate in infected cells prior to budding at the plasma
membrane.
DISCUSSION
In the present study, two distinct forms of putative
assembly intermediates, detergent-resistant and de-
tergent-sensitive complexes, have been detected and-
characterized in HIV-1-infected CD41 T cells. As char-
acterized by equilibrium-density centrifugation and
size column chromatography (Y.-M. Lee and X.-F. Yu,
unpublished results), the DRC was identified as a
large oligomeric structure composed of Pr55Gag,
Pr160Gag-Pol precursor molecules, and two RTp66-re-
lated cleavage intermediates of Pr160Gag-Pol precur-
sors. The DRC could easily be distinguished from
released mature or immature viral particles by differ-
ences in density, sensitivity to protease digestion, and
sensitivity to nonionic detergent: The density of the
DRC (1.10–1.13 g/ml) was lower than that of either
released mature or immature viral particles (1.15–1.17
g/ml); proteolytic digestion with trypsin or protease K
disrupted the DRC but had little effect on released viral
particles; and although the DRC was resistant to Triton
from the sucrose gradient was pelleted by a high-speed centrifugation
as described under Materials and Methods. Density of the sucrose
gradient is indicated (A, top). Viral proteins in the pelleted materials
were separated by SDS–PAGE and visualized by immunoblotting with
an HIV-11 human serum (A, bottom) and a mouse monoclonal anti-
RTp66 antibody (B). Density of fractions 5–7, 1.15–1.18 g./ml; density of
fractions 8–12, 1.10–1.13 g/ml.
FIG. 6. Identification of a detergent-sensitive complex (DSC) in HIV-
1-infected CD41 T cells. Homogenates of infected CD41 T cells were
prepared as described under Materials and Methods. The postnuclear
supernatant was separated by a discontinuous sucrose equilibrium-
density centrifugation without Triton X-100 pretreatment. Each fraction
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FIG. 7. Treatment of DSC and released viral particles with protease K and 1 M NaCl. (A, B, and C) Postnuclear supernatants of HIV-1-infected cell
homogenates were prepared as described in Fig. 6. The supernatants were subjected to a discontinuous sucrose equilibrium-density gradient without
further treatment (A), with 5 mg/ml protease K treatment at 37°C for 30 min (B), or with 1 M NaCl treatment at room temperature for 10 min (C). (D,
E, and F) The concentrated released mature viral particles prepared as described in Fig. 3 were also subjected to the sucrose equilibrium-density
centrifugation without further treatment (D), with 5 mg/ml protease K treatment (E), or with 1 M NaCl treatment (F) under the same conditions. Fractions
were pelleted and analyzed by SDS–PAGE and immunoblotting with an HIV-11 human serum. Densities of fractions 2–5, 5–7, 8–12, and 15–18 are
1.18–1.22, 1.15–1.17, 1.10–1.13, and 1.02–1.07 g/ml, respectively. Lane V, protein pattern of the mature viral proteins; lane M, molecular mass markers.
X-100, mature viral particles were disrupted. Immature
viral particles were not disrupted by 1% Triton X-100.
However, the naked immature capsids that were gen-
erated when the lipid membrane was removed by
nonionic detergent were even denser (.1.23 g/ml)
than the immature viral particles (1.15–1.17 g/ml). It is
not clear why the DRC has such a low density, since
size column chromatography and ultracentrifugation
experiments suggested that the DRC is a large protein
complex. Attempts to visualize the purified DRC by
TEM did not reveal any recognizable viral structure,
although under the same condition budding virus was
detected from the infected cells (data not shown).
In addition to the DRC, a putative assembly interme-
diate that is sensitive to nonionic detergent (DSC) was
also detected in HIV-1-infected CD41 T cells. Unlike the
DRC, the DSC showed a protein profile and density that
were very similar to those of released mature virions.
However, it could still be distinguished from these ma-
ture viral particles: Most of the DSC were disrupted by
protease K digestion, whereas the released mature viri-
ons were relatively resistant to the same treatment; this
result indicates that most of the DSC are not completely
enveloped by a cellular lipid bilayer. In addition, the
density of the DSC could be altered by treatment with 1
M NaCl, whereas the density of released mature virions
was unaffected.
The fact that the DSC could be disrupted by nonionic
detergent raises the possibility that its formation might
be dependent on an association with lipid membrane.
This possibility was supported by the results of experi-
ments characterizing the formation of DRC and absence
of DSC in a myristylation2 mutant of HIV-1 Gag and
Gag-Pol proteins. Although the DRC was readily de-
tected in the CD41 T cells and HeLa cells constitutively
expressing unmyristylated Gag and Gag-Pol, the forma-
tion of DSC was not observed. It has been well estab-
lished that myristylation of Gag molecules is required in
most retroviruses including HIV-1 in order for tight mem-
brane association of Gag molecules and formation of
FIG. 8. Assessment of the requirement for myristic acid modification of Gag proteins for the formation of DRC and DSC. A mutant CD41 T cell line
(Myr2) lacking the myristic acid modification to the N-terminus of Gag proteins was generated as described under Materials and Methods. (A, B, and
C) The sucrose gradient technique in Fig. 2 was used to detect DRC in mutant Myr2 cells. Postnuclear supernatants from wild-type Myr1 cells and
mutant Myr2 cells were prepared and incubated with 1% Triton X-100, then subjected to sucrose equilibrium-density centrifugation (A, B, top).
Fractions were pelleted and the proteins in the pelleted materials were separated by SDS–PAGE. Immunoblotting with an HIV-11 human serum
revealed viral proteins in the DRC from wild-type Myr1 cells (A, bottom) and mutant Myr2 cells (B, bottom). (C) Fractions 8 and 9 from both wild-type
Myr1 cells and mutant Myr2 cells were immunoblotted with a mouse monoclonal anti-RTp66 antibody to detect RTp66-related cleavage intermediates
of Pr160Gag-Pol precursors (arrowheads). (D) To detect DSC in mutant Myr2 cells, the postnuclear supernatant from mutant Myr2 cells was prepared
and divided in half as described in Fig. 6. Each aliquot was subjected to sucrose equilibrium-density centrifugation without (D, top) or with 1% Triton
X-100 treatment (D, bottom). Fractionation and pelleting were followed by immunoblotting with an HIV-11 human serum. Lane V, protein profile of
mature viral proteins; lane M, molecular mass markers. Density of fractions 9–11, 1.10–1.13 g/ml.
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extracellular viral particles to occur (Rein et al., 1986;
Delchambre et al., 1989; Gheysen et al., 1989; Gottlinger
et al., 1989; Jacobs et al., 1989; Bryant and Ratner, 1990;
Weaver and Panganiban, 1990; Hayakawa et al., 1992;
Wang and Barklis, 1993; Yuan et al., 1993; Zhou et al.,
1994). These results suggest that the formation of DRC is
unlikely to be strictly dependent on the presence of
cellular lipid membrane.
In the infected cell, the nascent Pr55Gag and Pr160Gag-Pol
precursors first have to oligomerize into a high-order struc-
ture that leads to the immature viral capsid in the late stage
of assembly. During morphogenesis, both precursors are
proteolytically processed into mature viral proteins in an
irreversible manner. In our study, the viral protein profile of
the DSC showed extensive proteolytic processing of
Pr55Gag precursors into mature proteins. Therefore, it
seems likely that DRC is the intermediate precursor to DSC,
which then buds and forms mature virions. The preformed
DRC in infected cells may be transported to the plasma
membrane through unknown cellular mechanisms. Upon
interaction with the lipid component of the plasma mem-
brane or some factor(s) near the membrane, the electron-
transparent DRC could begin to be transformed into other
assembly intermediates such as the DSC. One character-
istic of such a transformation would be the condensation of
the viral protein complex, which leads to the production of
an electron-dense craescent-shaped structure that could
be observed along the plasma membrane. The myristic
acid modification at the N-terminus of the Gag proteins may
be required for efficient intracellular transport or membrane
association of the DRC. It appears that when this modifica-
tion does not take place, the transformation from DRC to
DSC is blocked. However, it is also possible that transfor-
mation from DRC to DSC is a prerequisite for membrane
association and subsequent virus budding.
One of the key differences between type C and type
B/D retroviruses is the extent to which they are depen-
dent on the availability of lipid membranes for formation
of the viral capsid. The purified full-length Gag protein
from the type D M-PMV can efficiently form immature
capsids in vitro in the absence of any lipid component
(Sakalian et al., 1996). In contrast, the in vitro formation of
immature capsid structures of HIV-1 by the full-length
Gag molecule is dependent on the presence of lipid
membranes (Lingappa et al., 1997). Although it has been
reported that immature viral capsids of HIV-1 can be
formed by in vitro translated, full-length Gag molecules in
the absence of exogenous lipid membranes (Spearman
and Ratner, 1996), the possibility that these viral struc-
tures were formed from some endogenous lipid compo-
nent in the in vitro transcription/translation reaction
could not be excluded. In fact, these viral structures had
a density of 1.15 g/ml, which is similar to that of immature
viral particles that contain lipid membranes. The naked
immature viral capsid should have a density .1.20 g/ml
(Lingappa et al., 1997). It is interesting that formation of
immature HIV-1 capsids in the absence of lipid mem-
brane has been observed for a truncated form of the
HIV-1 Gag molecule (Campbell and Vogt, 1995). In their
study, the truncated Gag molecules lacked the MA do-
main. Intracellular assembly of viral capsid structures
has also been observed in a mutant expressing a trun-
cated HIV-1 Gag molecule with a large MA deletion
(Spearman et al., 1994). It is curious that in the presence
of the MA domain, the assembly of capsid structures that
is visible by electron microscopy requires lipid mem-
brane. It is interesting that the determinant for type-D
versus type-C morphogenesis in M-PMV is also located
in the MA domain (Rhee and Hunter, 1990).
The detection of DRC containing unmyristylated
Pr55Gag and Pr160Gag-Pol precursor molecules raises the
possibility that interactions between individual Gag pre-
cursors and between Gag and Gag-Pol precursors are
initiated before the precursors are targeted to the intra-
cellular membrane compartment. This conclusion is con-
sistent with previous observations that unmyristylated
Pr160Gag-Pol could be efficiently incorporated into myri-
stylated Pr55Gag particles (Park and Morrow, 1992; Smith
FIG. 8—Continued
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et al., 1993). It is not clear whether HIV-1 Gag assembly
is mediated through stepwise intermediates in a process
similar to that in poliovirus (reviewed in Ansardi et al.,
1996) or whether it is a continuous process in which
more and more Gag molecules are added to a preformed
nucleus. The former possibility is supported by a recent
in vitro study of HIV-1 capsid morphogenesis in which
the Pr55Gag precursors of HIV-1 were found to be assem-
bled into immature capsid structure in a multistep and
ATP-dependent manner (Lingappa et al., 1997). Although
we performed an electron microscopic study to visualize
putative assembly intermediates, we were unable to
identify any viral structures (data not shown). It is possi-
ble that such assembly intermediates are not sufficiently
electron-dense to be distinguished from the background.
It is conceivable that a regular structure may not yet be
organized in the putative assembly intermediates. Alter-
natively, preparation of the samples for electron micros-
copy may have had a deleterious effect on the regularity
or stability of the structures, making it impossible to
visualize these intermediates.
The newly identified DRC is an appealing target for an
inhibitor of retroviral assembly. The potential value of
such an inhibitor is supported by the fact that the DRC in
the myristylation2 mutant was preformed in the early
stage of retroviral assembly but not released from the
cell surface at the late stage. Further investigation of the
role of myristylation and other functional domains of the
Gag protein in HIV-1 morphogenesis may lead to the
identification of a specific inhibitor that can block assem-
bly at the DRC step during the course of HIV-1 infection.
MATERIALS AND METHODS
Antibodies and cell culture
An HIV-1-positive human serum was obtained from an
HIV-1-infected subject in Baltimore, MD. The rabbit poly-
clonal anti-CAp24 antiserum, rabbit polyclonal anti-
RTp66 antiserum, and mouse monoclonal anti-RTp66 an-
tibody were obtained from the AIDS Research and Ref-
erence program, NIH, Bethesda, MD. The alkaline
phosphatase (AP)-conjugated goat anti-rabbit IgG used
for immunoblotting was purchased from Sigma Immuno
Research. AP-conjugated goat anti-human IgG and AP-
conjugated goat anti-mouse IgG were purchased from
Jackson Immuno Research Laboratories, Inc.
COS-7 cells were obtained from the American Type Cul-
ture Collection. They were maintained in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% fetal bovine
serum, 100 units/ml penicillin, and 100 mg/ml streptomycin.
SupT-1 and H9 cell lines were grown in RPMI 1640 with 10%
fetal bovine serum and antibiotics. Media and reagents for
cell culture were purchased from Gibco Laboratories Life
Technologies Ltd., Gaithersburg, MD.
Construction of proviral DNA
All HIV proviral plasmids were based on the infectious
molecular clone of HXB2Neo described previously (Lee
et al., 1997). To generate the HXB2DPOLNeo proviral
plasmid, PCR was performed to amplify the whole gag
gene, introducing an EcoRI site at nucleotide 1839 with
the 39 oligo spanning nucleotides 1825–1854 (59-AGT
TGC CCC CGA ATT CTT ATT GTG ACG AGG-39) and the
59 oligo spanning nucleotides 320–349 (59-GGC TAG
AAG GGA ATT CAT GGG TGC GAG AGC-39). The SpeI–
EcoRI fragment of the PCR-amplified DNA was ligated
with the SpeI–EcoRI-digested HXB2Neo plasmid. The
resulting HXB2DPOLNeo proviral plasmid had a deletion
in the pol gene from nucleotide 1839 to 5289. To generate
the HXB2Pr2Neo proviral plasmid, the SpeI–SalI frag-
ment from pGPpr2 (Park and Morrow, 1992) was cloned
into the HXB2Neo proviral plasmid.
For the infectious HXB2Hygro construct, the hygromy-
cin resistance gene (hygroR) was PCR-amplified from
pCEP4 (Invitrogen) using primers incorporating ClaI and
XhoI sites at the 59 and 39 ends (59-GCC GCA GAT CGA
TCG ATA TGA GAT ATG AAA-39 and 59-TTA GCC TCC
CCC ACT CGA GCT ATT CCT TTG-39). These ClaI–XhoI
fragments containing the hygromycin resistance gene
were cloned into the HXB2Neo construct to replace the
neo gene. The isogenic myristylation-minus mutant pro-
viral plasmid (Myr2) was constructed by swapping the
ApaI–ApaI fragment from the MGA plasmid (Yuan et al.,
1993) into HXB2Hygro.
Transfection of cells
H9 HXB2Neo cells have been described previously
(Lee et al., 1997). To establish stable H9 DPOL and H9
Pr2 cell lines, H9 CD41 T cells were directly transfected
with HXB2DPolNeo and HXB2Pr2Neo proviral DNA by
lipofection as described previously (Felgner et al., 1987).
After 24 h, the transfected H9 cells were selected with
G418 (1.2 mg/ml) as described previously (Lee et al.,
1997). The established H9DPol and H9Pr2 cell lines
were maintained in RPMI 1640 with 10% fetal bovine
serum, antibiotics, and 0.4 mg/ml G418.
To generate the wild-type Myr1 and myristylation2
mutant Myr2 cell lines, SupT-1 CD41 T cells were di-
rectly transfected with either wild-type HXB2Hygro or
HXB2Myr2Hygro plasmids by lipofection. At 24 h after
transfection, the transfected cells were washed once
with complete medium and selected with the antibiotic
hygromycin B (0.8 mg/ml) for 2–3 weeks. The established
cell lines were maintained in RPMI 1640 with 10% fetal
bovine serum, antibiotics, and 0.2 mg/ml hygromycin B.
Equilibrium-density centrifugation
Cells were harvested by low-speed centrifugation and
washed twice in RPMI 1640 medium, then resuspended
in hypotonic buffer [10 mM KCl, 20 mM Tris–HCl (pH 7.8),
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1 mM EDTA, 0.1% 2-mercaptoethanol, 2 mg/ml aprotinin]
and incubated at 4°C for 20 min. The cells were homog-
enized on ice in a tight-fitting glass B Dounce homoge-
nizer, and nuclei and unbroken cells were removed by
centrifugation at 2000 rpm for 10 min. Five milliliters of
the resulting postnuclear supernatant was mixed with
0.5 ml of 10% Triton X-100 for 10 min at room temperature.
A 16 to 60% discontinuous sucrose equilibrium-density
gradient in TNE buffer [10 mM Tris (pH 7.8), 100 mM
NaCl, 1 mM EDTA) was prepared in advance by layering
2.3 ml of each stock sucrose solution (from 60 to 16% in
4% increments) in the bottom of a 36-ml ultracentrifuge
tube. The gradients were then ultracentrifuged in a Sor-
vall AH-6295 rotor at 20,000 rpm (71,935 g) for 12 h at 4°C.
Fractions (1.9 ml each) were collected by puncturing the
tube at the bottom of sucrose gradient. Each fraction was
stored at 4°C until particulate materials were pelleted by
ultracentrifugation. For the pelleting procedure, each
fraction was diluted with 6.5 ml of phosphate-buffered
saline (PBS), pH 7.8, and ultracentrifuged in a Sorvall
T1270 rotor at 40,000 rpm (146,550 g) for 1 h at 4°C. The
resulting pellet was resuspended with radioimmunopre-
cipitation assay lysis buffer [0.15 M NaCl, 0.05 M Tris–
HCl (pH 7.2), 1% Triton X-100, 1% sodium deoxycholate,
0.1% sodium dodecyl sulfate). Aliquots of each fraction
were dissolved in SDS sample buffer and heated for 5
min at 95°C before loading onto 12% SDS–polyacrylam-
ide gels.
Immunoblotting
The pelleted proteins were separated by SDS–PAGE
under reducing conditions and passively transferred to
a pair of nitrocellulose membranes (Schleicher &
Schuell, Germany) for 24 h as described previously
(Lee et al., 1997). The nitrocellulose membranes were
blocked with 3% nonfat dry milk in washing solution
(0.2% Tween 20 in PBS) at room temperature for 1 h.
They were then washed three times with washing
solution and incubated at room temperature for 1 h
with the HIV-11 human serum, the rabbit polyclonal
anti-CAp24 antiserum, the rabbit polyclonal anti-RTp66
antiserum, or the mouse monoclonal anti-RTp66 anti-
body. Primary antibody-decorated membranes were
washed three times with washing solution and incu-
bated with the appropriate AP-conjugated secondary
antibody at room temperature for 1 h. The membranes
were washed three times with washing solution and
once with PBS. Protein bands were visualized by in-
cubation with 5-bromo-4-chloro-3-indolyl-phosphate
and nitroblue tetrazolium as substrate.
Trypsin digestion
Precleared postnuclear supernatants from infected
cell homogenates were prepared as described above
and divided in half. One-half of each supernatant was
incubated with 5 mg/ml trypsin (Boehringer Mannheim,
Germany) at 37°C for 30 min; trypsin activity was then
inhibited by addition of an excess antitrypsin inhibitor (30
mg/ml) (Boehringer Mannheim). The other half of each
sample was simultaneously incubated without trypsin as
a control. Both aliquots were then treated with 1% Triton
X-100 at room temperature for 10 min to identify deter-
gent-resistant putative assembly intermediates. The de-
tergent-treated aliquots were subjected to a 16–60% dis-
continuous sucrose equilibrium-density gradient, and the
resulting fractions were analyzed by SDS–PAGE and
immunoblotting.
To isolate and characterize released mature viral
particles, cell culture supernatant was collected from
HIV-1-infected CD41 T cells and precleared by pellet-
ing at 3000 rpm (Sorvall RT6000B, Du Pont) for 20 min.
The resulting supernatant was cleared by filteration
(0.22 mm pore size) and concentrated by ultracentrif-
ugation through a 20% sucrose cushion. The viral
particles were resuspended in hypotonic buffer, incu-
bated at 4°C for 20 min, then homogenized in a tight-
fitting glass B Dounce homogenizer and centrifuged at
2000 rpm (Sorvall RT6000B, Du Pont) for 10 min. After
centrifugation, the supernatant was divided in half,
and one-half was incubated with trypsin. The control
and trypsin-treated aliquots were then fractionated on
a 16–60% discontinuous sucrose equilibrium-density
gradient, and the fractions were analyzed by SDS–
PAGE and immunoblotting.
Protease K digestion and high-salt treatment
A 15-ml sample of precleared postnuclear superna-
tant from a homogenate of HIV-1-infected CD41 T cells
was prepared as described above by equilibrium-den-
sity centrifugation and divided into three equal sam-
ples. One sample was incubated with 5 mg/ml pro-
tease K solution (Boehringer Mannheim) at 37°C for 30
min. The activity of protease K was then inhibited by
addition of 30 mg/ml leupeptin (Boehringer Mann-
heim). As a control, a second sample was also incu-
bated at 37°C without any addition. The third sample
was incubated at room temperature for 10 min after
addition of 1 M NaCl. The three samples were then
centrifuged through a 16–60% discontinuous sucrose
equilibrium-density gradient.
Released viral particles were also cleared of cell
debris, concentrated, and homogenized as described
above. The viral particles were either left untreated or
subjected to 5 mg/ml protease K treatment at 37°C for
30 min or 1 M NaCl treatment at room temperature for
10 min under the conditions described above, then
loaded on a 16–60% discontinuous sucrose equilibri-
um-density gradient. After fractionation, each fraction
was pelleted and analyzed by SDS–PAGE and immu-
noblotting.
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